Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    "Aberrant Crypt Foci"
Show Display Options
Rank Status Study
1 Terminated The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon
Condition: Aberrant Crypt Foci
Interventions: Drug: sulindac;   Drug: curcumin
2 Completed Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
Conditions: Healthy, no Evidence of Disease;   Tobacco Use Disorder
Interventions: Other: laboratory biomarker analysis;   Other: pharmacological study;   Drug: curcumin
3 Completed Colonoscopic Removal of Aberrant Crypt Foci: a Prospective, Randomized, Blinded Trial
Condition: Colorectal Neoplasms
Interventions: Procedure: Surgical removal of ACF;   Procedure: Colonoscopic evaluation only
4 Active, not recruiting Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
Conditions: Adenomatous Polyp;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage IIA Colon Cancer;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years